Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity
NCT07767175Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Aug 2026
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 1, randomised trial of NNC0721-8060 in obesity (3 arms), sponsored by Novo Nordisk. Primary endpoints: Number of treatment emergent adverse events at 113 days and Change from baseline in body weight at 85 days. Started Aug 2026; status: recruiting.
02
Drugs
NNC0721-8060
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07767175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07767175.